A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk MDS and Anemia

Summary

This research is being conducted to asses if HT-6184 is effective in the treatment of Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS) and Symptomatic Anemia. The study includes a 28-day Screening Period followed by a 16- or 32-week Treatment Period. Participants will be monitored at each cycle for drug tolerance, safety, and hematological response. A response assessment will occur after 16 weeks of study treatment.

Timeline

Start

2023-12-09

Primary completion

2026-01-08

Completion

2026-05-25

Drugs

Indications